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TOP CITED PAPERS IN INTERNATIONAL PSYCHOGERIATRICS: 3. EFFICACY OF DONEPEZIL ON
BEHAVIORAL SYMPTOMS IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER’S DISEASE
Reflection
The article under discussion (Gauthier et al., 2002)
is based on a sub-analysis from the Moderate to
Severe Alzheimer Disease (MSAD) Study, which
was an investigator-driven attempt to expand the
use of cholinesterase inhibitors (ChEIs) in the
severe stages of Alzheimer’s disease. The results of
MSAD have been published in Neurology (Feldman
et al., 2001), including the Neuropsychiatric
Inventory (NPI) total score, which showed a
statistically significant difference between placebo
and donepezil at the 24-week end-point. In the
article published in International Psychogeriatrics
in 2002, the investigators of the MSAD Study
analyzed which behavioral symptoms drove the
difference in NPI total score. This publication has
led to a new way of analyzing data on behavioral and
psychological symptoms of dementia (BPSD) from
randomized clinical trials: (1) individual items of
the NPI are analyzed at baseline for frequency, and
clusters can be defined from the population under
study; (2) symptoms not present at baseline are
examined for emergence during the study period;
(3) symptoms present at baseline are examined for
improvement during the study period.
In the MSAD Study the total NPI-12 score dif-
ference at week 24 between donepezil and placebo
was 5.6 (p < 0.001). Based on baseline individual
NPI items scores, out of three clusters identified
from a factor analysis a cluster of five items was
identified as being of most clinical significance
(agitation/aggression, depression/dysphoria, anxi-
ety, apathy/indifference, irritability/lability); this
“NPI-5” showed statistically significant difference
between donepezil and placebo at weeks 4, 18 and
24. More importantly, the analysis of symptoms
present at baseline showed improvement at week 24
for anxiety, apathy/indifference, irritability/lability.
This information can be useful for clinicians
monitoring treatment responses in individual
patients taking donepezil. No individual symptom
stood out in the prevention of emergence of
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individual symptoms not present at baseline,
contrary to placebo-controlled memantine studies
where the incidence of agitation/aggression is
significantly reduced over 24 weeks (Gauthier et al.,
2005). One final observation from the 2002 sub-
analysis: only patients not taking psychoactive
medications at baseline showed a significant
difference from placebo at each visit and at week-24
end point. This suggests that the behavioral effects
of ChEIs are diluted by concomitant psychotropic
medications, a partial explanation for the difficulty
in proving benefit using donepezil in other studies.
Since the paper’s publication in International
Psychogeriatrics, the NPI item sub-analysis has
led to the observation of an anti-agitation effect
of memantine in moderate to severe stages of
Alzheimer’s disease (Cummings et al., 2006;
Gauthier et al., 2008). A randomized clinical trial
comparing memantine to placebo is under way in
Canada with the specific aim of confirming in a
prospective study a reduction in agitation, using
the NPI and the Cohen-Mansfield Agitation Index,
and a reduction in the use of psychotropic drugs,
as suggested in a recent analysis from the French
National Health Care Database (Vidal et al., 2008).
I think the publication in International
Psychogeriatrics of the behavioral sub-analysis
of the MSAD Study has facilitated the use of
behavioral outcomes in randomized clinical trials,
will help regulatory agencies to recognize beneficial
drug effects on BPSD, and will accelerate the
reimbursement of such drugs by third-party payers.
The behavioral sub-analysis may also help to
provide evidence-based information to clinicians
about which specific behavioral symptom or cluster
of symptoms improve or decrease in incidence
when using a specific drug or drug class.
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Commentary
It is now well accepted that non-cognitive features
are at least as important, if not more important,
than cognitive impairment in Alzheimer’s disease,
that some of these symptoms have (at least in part)
a cholinergic basis and that there is evidence that
anti-dementia drugs can improve non-cognitive as
well as cognitive symptoms (Ames et al., 2008).
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However, all three statements were certainly not
widely accepted, or even accepted at all, at the time
when Gauthier and colleagues were planning and
conducting their important double-blind, random-
ized controlled trial of donepezil against placebo in
moderate to severe Alzheimer’s disease. The study
was not the first to show an effect of cholinesterase
medication, in this case donepezil, on behavioral
symptoms, but it was one of the first to examine in a
systematic way which particular types of behavioral
and psychological symptoms of dementia (BPSD)
were affected. BPSD has been an extremely helpful
term as a profile-raiser for the importance of non-
cognitive symptoms in dementia, but one of the
drawbacks with such an umbrella term is that
some view it incorrectly as a unitary concept or
dimension, for example one that can either be
helped or not helped by various interventions,
whether pharmacological or psychosocial (Bird
et al., 2007). In fact, BPSD clearly represent a
constellation of signs and symptoms, some related
closely to each other but others quite distinct,
some of which may share common neurobiological
mechanisms while others will not. It follows,
therefore, that some treatments may be effective for
some types of BPSD, but have little effect on (or
even worsen) others (Rabinowitz et al., 2007).
By utilizing sub-analyses from the very widely
used, simple, yet comprehensive Neuropsychiatric
Inventory (NPI), Gauthier et al. (2002) clearly
showed in their paper differential effects on some
symptoms with particular effects for improving
apathy, anxiety and dysphoria. There was also a
significant change in a cluster which contained delu-
sions and hallucinations. These findings accord well
with neurochemical evidence that both psychosis
and apathy are to some extent mediated by cholin-
ergic deficit. Interestingly, in this study, there was
no effect on agitation as a symptom, which has now
been supported by a large randomized controlled
trial of the same medication, donepezil, in people
with Alzheimer’s disease and clinically significant
agitation which showed absolutely no suggestion of
benefit of donepezil over placebo (Howard et al.,
2007). Gauthier and colleagues analyzed their data
carefully. It is important to note that they found
no detrimental effects in terms of increased side
effects either in those on or not taking antipsychotics
(in particular parkinsonism did not significantly
worsen). It is a testament to the significance of this
paper that many subsequent papers have tackled
analysis of NPI subscales in a similar way, and the
effect on non-cognitive symptoms has now been
supported by independent meta-analyses, such as
from the Cochrane collaboration (Birks and Harvey,
2006). This is especially important in view of limit-
ations on the prescribing of other drugs such as an-
tipsychotics (Haw et al., 2008). This remains a key
area of research and the authors quite rightly point
out that one limitation of their study was that it did
not include people who were selected on the basis of
having prominent BPSD, so in many ways findings
may not be generalizable to people for whom
these symptoms are targets for treatment in routine
clinical practice. This paper and commentary also
highlight that, although there are some other studies
ongoing, there remains a great need for many
more well-designed studies seeking to investigate
the specific effects of drugs, both anti-dementia
drugs and other agents (Konovalov et al., 2008),
which may potentially help troublesome behaviors
and distressing symptoms in those with dementia.
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